Search

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

Boehringer welcomes 2023 Gold Report

Boehringer welcomes 2023 GOLD Report Positioning LAMA/LABA as preferred treatment

Boehringer inhalers now available at $35 a month for eligible patients

Boehringer COPD and asthma inhalers now available at $35 a month for eligible patients

New GPP Consensus Statement Released

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

Immunology

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in immunology.

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.

Poultry vaccine site in Georgia continues to reduce carbon emissions

Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere

Positive results reported in HER2 mutated lung cancer

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Are combination therapies the answer to battling KRAS cancers?

Dr Ulrich Dünzinger and Kristie Fernamberg talk about their work with the SOS1 KRAS inhibitor to block tumour-triggering signal

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

Real-world study shows sequencing of Gilotrif

A day of giving back at Pegasus Therapeutic Riding

Take a look at our volunteer day spent refreshing a farm committed to equine therapy.

Bigger Role in Ensuring Food Security | Boehringer Ingelheim US

As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Results announced from EMPACT-MI phase III trial

Results announced from EMPACT-MI phase III trial in adults following a heart attack.

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

Funding Opportunities

Improving Access to Clinical Trials

Walgreens and Boehringer Ingelheim Are Partnering to Improve Diversity in Clinical Trials

Duluth, Georgia

Boehringer Ingelheim Animal Health employs about

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers

Search

Statement by Boehringer Ingelheim on selection of Jardiance® (empagliflozin) by the Centers for Medicare and Medicaid Services (CMS) Drug Price Negotiation Program

Boehringer welcomes 2023 Gold Report

Boehringer inhalers now available at $35 a month for eligible patients

New GPP Consensus Statement Released

Immunology

BI initiates Study of Sequencing in EGFR Lung Cancer | BI US

FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

Poultry vaccine site in Georgia continues to reduce carbon emissions

Positive results reported in HER2 mutated lung cancer

Are combination therapies the answer to battling KRAS cancers?

Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC

A day of giving back at Pegasus Therapeutic Riding

Bigger Role in Ensuring Food Security | Boehringer Ingelheim US

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Results announced from EMPACT-MI phase III trial

Boehringer Ingelheim and Yale Clinical and Translational Research Accelerator collaborate to explore potential benefits of digital health technologies for adults with heart failure

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care

Exploring beyond boundaries for innovation in animal health

Funding Opportunities

Improving Access to Clinical Trials

Duluth, Georgia

Boehringer Ingelheim and OSE Immunotherapeutics Announce Global Immuno-Oncology Partnership to Develop a Pioneering Checkpoint Inhibitor for the Treatment of Advanced Solid Tumors

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors